Is ADC Therapeutics SA halal to invest in?

According to Musaffa's Shariah screening methodology, ADC Therapeutics SA (ADCT) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is ADC Therapeutics SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes ADC Therapeutics SA using these criteria to determine its compliance status.

Can Muslims buy shares of ADC Therapeutics SA?

Muslim investors may consider investing in ADC Therapeutics SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is ADC Therapeutics SA classified as NOT HALAL?

Musaffa determines the Shariah status of ADC Therapeutics SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for ADC Therapeutics SA updated?

The Shariah compliance status of ADC Therapeutics SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like ADC Therapeutics SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of ADC Therapeutics SA?

You can check the latest Shariah compliance status of ADC Therapeutics SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ADCT Shariah Compliance

Screening Methodology: AAOIFI

UNLOCK FOR FREE

Last Updated: March 12, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for ADC Therapeutics SA (ADCT)

Based on 12 analysts giving stock ratings to ADC Therapeutics SA in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

ADC Therapeutics SA. Stock Analysis ADCT

United States Health Care Small Cap Report: 2025 Annual

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. The company is headquartered in Epalinges, Vaud and currently employs 263 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

Key Statistics of ADC Therapeutics SA (ADCT)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$3.69$3.81

Today's Open

$3.69

Volume

630.04K

P/E Ratio (TTM)

52 Week Range

$1.05$4.98

Market Cap

447.20M

Avg. Volume

848.85K

Dividend Yield

Financial Metrics & Statements of ADC Therapeutics SA (ADCT)

FAQ's for ADC Therapeutics SA (ADCT)

According to Musaffa’s Shariah screening methodology, ADC Therapeutics SA (ADCT) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.